Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective First-In-Human Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa (adRP) Due to the P23H Mutation in the RHO Gene

NCT04123626 is registered in ClinicalTrials.gov with ProQR Therapeutics as lead sponsor.

NCT NCT04123626
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04123626 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective First-In-Human Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa (adRP) Due to the P23H Mutation in the RHO Gene
Lead sponsor
ProQR Therapeutics
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
October 7, 2019
Completion date
June 7, 2022
Enrollment
11 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

autosomal dominant retinitis pigmentosa, eye diseases, eye diseases, hereditary, retinal disease, retinal dystrophies, retinitis, vision disorders, vision tunnel